A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a growth oriented and diversified next generation biotech, genomics and consumer products company company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. (“Nebula”) and DNA Complete, Inc. ("DNA Complete"). Our wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”) is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand. Previously we offered a broad array of COVID-19 related clinical diagnostic and testing services including polymerase chain reaction (“PCR”) testing for COVID-19 and Influenza A and B as well as rapid antigen testing for COVID-19 through our wholly-owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.1M | - | 35M | 123M | - | 15M |
| Net Income | -42M | -53M | -17M | 18M | 6.3M | -2.1M |
| EPS | $-17.80 | $-26.10 | $-9.80 | $10.20 | $4.00 | $-1.80 |
| Free Cash Flow | -10M | -18M | -14M | 25M | -18M | -4.3M |
| ROIC | -174.5% | -208.7% | -32.1% | 39.0% | 30.9% | -10.3% |
| Gross Margin | 191.4% | - | 44.5% | 57.6% | - | 31.7% |
| Debt/Equity | 0.89 | 1.08 | 0.10 | 0.00 | 0.17 | 0.95 |
| Dividends/Share | $0.00 | - | $3.00 | $3.00 | $2.90 | $4.93 |
| Operating Income | -27M | -39M | -21M | 24M | 9.8M | -2.1M |
| Operating Margin | -2496.6% | - | -60.7% | 19.2% | - | -14.3% |
| ROE | -607.8% | -188.1% | -29.7% | 30.2% | 18.1% | -19.5% |
| Shares Outstanding | 5M | 2M | 2M | 2M | 2M | 1M |
ProPhase Labs, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 6.8% with a gross margin of 44.6%. At current prices, the estimated annualized return to fair value is -7.7%.
ProPhase Labs, Inc. (PRPH) has a 5-year average return on invested capital (ROIC) of 6.8%. This is below average and may indicate limited pricing power.
ProPhase Labs, Inc. (PRPH) has a market capitalization of $679K. It is classified as a small-cap stock.
ProPhase Labs, Inc. (PRPH) does not currently pay a regular dividend.
ProPhase Labs, Inc. (PRPH) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ProPhase Labs, Inc. (PRPH) generated $-18 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ProPhase Labs, Inc. (PRPH) has a debt-to-equity ratio of 1.08. This indicates moderate leverage.
ProPhase Labs, Inc. (PRPH) reported earnings per share (EPS) of $-26.10 in its most recent fiscal year.
ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -188.1%. A negative ROE may indicate losses or negative equity.
ProPhase Labs, Inc. (PRPH) has a 5-year average gross margin of 44.6%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for ProPhase Labs, Inc. (PRPH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ProPhase Labs, Inc. (PRPH) has a book value per share of $3.60, based on its most recent annual SEC filing.